At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, and 1 other intervention for Estrogen Receptor Negative and 6 related conditions. Completed, enrolled 37 participants across 8 sites.
Detailed Summary
This phase II trial studies how well trametinib and v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor GSK2141795 work in treating patients with triple-negative breast cancer (breast cancer cells that do not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 \[HER2/neu\] protein) that has spread to other places in the body. Trametinib and Akt inhibitor GSK2141795 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Given PO